论文部分内容阅读
目的探讨甲基强的松龙在复发缓解型多发性硬化患者治疗中的应用效果。方法 118例复发缓解型多发性硬化患者进行研究,以治疗方式的不同将患者分为对照组和观察组,每组59例。对照组患者采用地塞米松治疗,观察组患者采用甲基强的松龙治疗,对比两组效果。结果治疗前,观察组患者tau蛋白、S100蛋白、白介素-23(IL-23)、白介素-17(IL-17)水平比较差异均无统计学意义(P>0.05)。治疗后,观察组患者tau蛋白及S100蛋白水平分别为(72.7±6.4)、(720.6±35.5)pg/ml;对照组治疗后分别为(66.9±7.7)、(688.6±40.3)pg/ml;治疗后观察组tau蛋白及S100蛋白水平均明显优于对照组,差异具有统计学意义(P<0.05);观察组患者治疗后IL-23、IL-17分别为(398.9±25.5)、(50.4±8.8)pg/ml;对照组患者治疗后分别为(487.7±32.2)、(68.6±14.3)pg/ml,观察组IL-23、IL-17水平均明显优于对照组,差异具有统计学意义(P<0.05)。治疗后随访1年,观察组患者平均复发次数为(0.8±0.1)次;对照组为(2.0±0.3)次,观察组复发次数明显少于对照组,差异具有统计学意义(P<0.05)。结论采用甲基强的松龙对复发缓解型多发性硬化患者进行治疗效果显著,有利于减少复发,有较高的临床推广价值。
Objective To investigate the effect of methylprednisolone in the treatment of patients with relapsing-remitting multiple sclerosis. Methods A total of 118 patients with relapsing-remitting multiple sclerosis were enrolled in this study. The patients were divided into control group and observation group with 59 patients in each group. Patients in the control group were treated with dexamethasone, and patients in the observation group were treated with methylprednisolone, comparing the two groups. Results Before treatment, the levels of tau protein, S100 protein, interleukin-23 (IL-23) and interleukin-17 (IL-17) in the observation group had no significant difference (P> 0.05). After treatment, the levels of tau protein and S100 protein in the observation group were (72.7 ± 6.4) and (720.6 ± 35.5) pg / ml, respectively; while those in the control group were (66.9 ± 7.7) and (688.6 ± 40.3) pg / After treatment, the levels of tau protein and S100 protein in the observation group were significantly better than those in the control group (P <0.05). The levels of IL-23 and IL-17 in the observation group were (398.9 ± 25.5) and (50.4 ± 8.8) pg / ml in the control group (487.7 ± 32.2) and (68.6 ± 14.3) pg / ml after treatment respectively. The levels of IL-23 and IL-17 in the observation group were significantly better than those in the control group Significance (P <0.05). The average number of recurrence in the observation group was (0.8 ± 0.1) times; the control group was (2.0 ± 0.3) times, the number of recurrence in the observation group was significantly less than that in the control group, the difference was statistically significant (P <0.05) . Conclusion The use of methylprednisolone in patients with relapsing-remitting multiple sclerosis treatment is significant, is conducive to reducing recurrence, have a higher clinical value.